55 results about "Surface Glycoproteins" patented technology

The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

A real-time assay coupled with a non-invasive tissue sampling was developed for the detection and quantification of fish viruses. As a proof of principles, data were presented for the detection and quantification of infectious hypodermal necrosis virus (IHNV) in trout. The primers were designed for IHNV nucleocapsid (N), and surface glycoprotein (G) genes, and trout &bgr;-actin and elongation factor-l&agr; (EF-I &agr;) were used as internal control for the assay. The reaction conditions for the real-time RT-PCR were optimized using cDNA derived from IHNV-infected Epithelioma papulosum cyprinid (EPC) cells. Using both N- and G-gene primers, IHNV was successfully detected in liver, kidney, spleen, adipose tissue and pectoral fin samples of laboratory-challenged and wild samples. The dissociation curves with a single melting peak at expected temperature (85° C. for the N-gene and 86.5° C. for the G-gene) confirmed the specificity of the N- and G-gene amplicons. The IHNV N- and the G-gene expression levels in different tissues of laboratory challenged samples were in the order of spleen, liver, kidney, adipose tissue and pectoral fin, however in the field-collected samples the order of gene expression was liver, kidney, pectoral fin, adipose tissue, and spleen. The N- and G-gene expressions in spleen were found to be dramatically lower in the field-collected samples compared to the laboratory-challenged samples indicating a potential difference in the IHNV replication in the laboratory as opposed to field conditions. The real-time PCR assay was found to be rapid, highly sensitive, and reproducible. Based upon the ability to detect the virus in pectoral fins a non-invasive detection method for IHNV and other fish viruses is developed. Such a non-invasive tissue sampling coupled with real-time PCR assay is very valuable for large-scale virus screening of fish in aquaculture facilities as well as for epidemiological studies.

Highly efficient gene transfer into primate-derived embryonic stem (ES) cells has successfully been achieved by using a simian immunodeficiency virus vector (SIV) pseudotyped with VSV-G protein, which is a surface glycoprotein of vesicular stomatitis virus (VSV) The present invention provides simian immunodeficiency virus vectors for gene transfer to primate ES cells. The method for gene transfer to primate ES cells using the vectors of the present invention is useful in, for example, research into embryology and disease, clinical applications, and experimental models for primates. The method is also useful in assaying and screening for genes and reagents able to enhance the specific differentiation of tissues or cells, and which are useful in preparing desired cells or tissues differentiated from ES cells.

The invention belongs to the technical field of medicines, and particularly relates to a 2019-nCoV subunit vaccine composition and an immunization method thereof. The vaccine composition is a surfaceglycoprotein subunit vaccine of fusion protein consisting of one or more surface glycoprotein subunits obtained from a 2019-nCoV virus strain and a TAT transmembrane sequence, is assisted by non-toxicglucopyranosyl lipid as an adjuvant, and is coated with liposome or exosome. The vaccine composition has the advantages of high antigen presentation efficiency, no toxic or side effect on a human body and no stimulation effect.

Peptides having activity of inhibiting infections of respiratory viruses and use of the same are disclosed. The peptides can be synthesized by chemical or genetic engineering methods, and they have functional domain capable of binding to surface glycoprotein of respiratory viruses and activity of inhibiting infections of respiratory viruses. The peptides are useful for blocking infections of respiratory viruses in target cells, for prevention / treatment of said infections, and for development of new prophylactic / therapeutic medicaments against respiratory viruses. Also disclosed are a kit for screening peptide capable of inhibiting said infections and the screening method. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic / therapeutic agents with broad-spectrum antiviral activities.

The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.

The invention provides a detection method and detection reagent kit for detecting 2019 novel coronavirus. PCR primers are two pairs of primers designed for detection of novel coronavirus ORF1ab and Surface glycoprotein genes. The detection reagent kit comprises Taq DNA polemerase mixed liquid, mixed liquid of the two pairs of primers, ddH2O, Marker, positive controls and negative controls. The detection method comprises the steps of using obtained sample cDNA as a template, and performing a PCR reaction by using the two pairs of primers; and performing agarose gel electrophoretic analysis on reaction products. According to the technical scheme provided by the invention, the 2019 novel coronavirus ORF1ab and Surface glycoprotein genes can be effectively detected. The method is high in specificity, high in sensitivity, short in detection period, rigorous and reliable in results and high in practicality. The invention provides an effective method for nucleic acid detection of the 2019 novel coronavirus.

The present invention provides recombinant respiratory syncytial viruses (RSV) in which all of the surface glycoprotein genes encoding the attachment protein G, the fusion protein F, and the Small Hydrophobic protein SH are deleted. The genes are replaced by a chimeric gene encoding a heterologous entry protein derived from the Vesicular Stomatitis Virus G protein or GP64 of baculovirus. Alternatively, the replacement proteins are provided in trans. Marker genes such as those encoding β-glucuronidase (GUS) and green fluorescent protein (EGFP) are also added to the upstream and downstream side of the hybrid gene for easy detection. These infectious recombinant respiratory syncytial viruses offer alternatives and improvements as vaccine candidates.